Dominick Bossé, MD MPH
@Dominick_Bosse
Followers
871
Following
2K
Statuses
705
GU/GI medical oncologist and assistant professor at U of Ottawa. Views are my own.
Ottawa, Ontario
Joined January 2016
RT @KidneyCancer_Ca: With the many advances in treatment options for #kidneycancer shared decision-making has never been more important. @D…
0
2
0
RT @tompowles1: Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st lin…
0
500
0
RT @montypal: Amazing to watch history being made (virtually at the moment) by @tompowles1 @bartsemc. Huge congrats to the #EV302 investiga…
0
28
0
RT @DrChoueiri: Simply "presidential"! @tompowles1 presents the first combinations thats beats chemotherapy in 1L mUC for survival!! At 17.…
0
69
0
RT @tompowles1: Neoadjuvant atezo in non-urothelial cancer subtypes led by @b_szabados @BartsECMC #ESMO23 . Firstly, the inconsistency in p…
0
40
0
RT @OncLive: ⭐️Dr. Daniel Heng gives an outstanding discussion on the road ahead in renal cell cancer. #OncLiveTakeOver @CParkMD #ESMO23 @…
0
10
0
RT @DrChoueiri: 🚨Please do not miss one of the most awaited Presidential sessions with 2 practice-changing studies in UC! 📍Madrid auditori…
0
28
0
RT @ckcis_ca: Hot off the press! Check out the latest CKCF Consensus Statement; "Adjuvant therapy for RCC: 2023."
0
11
0
RT @DrChoueiri: Amazing podcast! Please read about the genesis of @IMDConline and our efforts with @DrDanielHeng with @Wanling50578056 @Me…
0
5
0
RT @CanUrolAssoc: 1 Meeting #CKCF2022 4 teams...some injuries later! We have a winning team w/ @lukelavallee @_kmcalpine @RodBreau . Thank…
0
9
0
RT @montypal: Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w t…
0
75
0
RT @DrChoueiri: It is this time of the year again: TOP 20 GU Oncology clinical trials published in 2021: Some negative, some positive, som…
0
227
0
RT @DrChoueiri: 8/ Phase 3 EV-301 trial showing improved PFS and OS with EV (vs. chemo) in patients with previously treated mUC @tompowles1…
0
3
0
RT @CanUrolAssoc: Claim your section 3 credits #OnDemand Advanced Renal Cell Carcinoma (aRCC) Script Concordance Test Learning Program #UR…
0
4
0
RT @tompowles1: RII PRISM study tests 3 monthly IPI vs standard IPI (3 weekly) as part of IPI/NIVO in mRCC (n=293). The modified regimen ha…
0
36
0
RT @tompowles1: A spectacular practice changing benifit for adding abiraterone to RT and ADT for high risk M0 Prostate cancer . 40% !!! Red…
0
79
0
RT @DrChoueiri: 1/ On the heels of @ASCO #ASCO21 plenary, we are happy to share the results of KEYNOTE-564 trial of adjuvant pembrolizumab…
0
166
0
RT @DrChrisHoimes: Enfortumab Vedotin now approved @US_FDA for post PD1 setting! - regardless of prior platinum- in pts with metastatic UC,…
0
9
0
RT @CanUrolAssoc: 16th Annual Meeting of the GU Med Oncs of 🇨🇦 #GUMOC2021 #GUMOC21 the virtual edition had 92 participants at peak! Here i…
0
1
0